GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
1.6k
c/trialwatch·posted 2 years ago by u/hsa_math

someone explain endpoint to me like I have not read a paper in years

Readout Cold Box ×9 Slow Clap ×1

I have had 18 orders now and I keep a table, so here is the honest summary rather than a vibe.

Material has been consistent. Communication has not. Shipping has varied by about 38 days on nominally the same lane, which matters more in summer than in February.

The independent number came back 98.4% against a claimed 98.6%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.

Batch number is in the comments. Ask if you want the method.

14,494 up / 12,919 down53% upvoted32 commentsid 164ypq2 Jan 2024

32 comments

17 in this archive, depth 4

best — the order this archive was captured in

u/cloudy_vial_carol92 points·2 years ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/hsa_mathOP65 points·2 years ago

dropout handling matters, especially on GI-heavy populations

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
u/hub_opssite staff16 points·2 years ago

dropout handling matters, especially on GI-heavy populations Counter-anecdote: opposite result, same dose.

Adding to this: hazard ratio is doing more work than the comment implies.

replysharereportpermalink
u/sofia_ferreira5 points·2 years ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/laila_almeida90 points·2 years ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/hsa_mathOP34 points·2 years ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
load more comments (3) →
u/anders_kuusela54 points·2 years ago

This is correct. Discontinuation arms show the regain reality.

replysharereportpermalink
u/cesar_ivaturi26 points·2 years ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/renal_outcomes_rMOD21 points·2 years ago

Flair changed to match the content. Read the sidebar before posting next time and we are square.

replysharereportpermalink
u/whois_wanda-18 points·2 years ago

Slight fix: the number was 97.6, not 97.9. Decimal point, but a fairly consequential one.

replysharereportpermalink
u/yara_mensah14 points·2 years ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/ines_boateng5 points·2 years ago

dropout handling matters, especially on GI-heavy populations

Yes, exactly this, and it is the bit that took me 54 weeks to accept.

replysharereportpermalink
u/plateau_patrol4 points·2 years ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/eu_apotheke_a7 points·2 years ago

Respectfully this is a sample of one presented as a finding.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.